The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Respiratory syncytial virus (RSV) is known to cause considerable respiratory infection-related morbidity and mortality worldwide.1,2 Estimates published in 2022 from the UK highlight the ...

The approval of RSV vaccines for seniors, including Pfizer's Abrysvo and GSK's Arexvy in May 2023, has driven significant uptake. The increasing elderly population and high hospitalization rates ...

Pune, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus Therapeutics Market Size & Growth Analysis: “According to SNS Insider, The Respiratory Syncytial Virus (RSV) Therapeutics ...

After hours: February 14 at 7:59:58 PM EST Loading Chart for PFE ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis. RSV occurs in epidemics almost every winter. People do not develop life-long ...